Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: the COGiTATE phase II study protocol. by Beqiri, Erta et al.
1Beqiri E, et al. BMJ Open 2019;9:e030727. doi:10.1136/bmjopen-2019-030727
Open access 
Feasibility of individualised severe 
traumatic brain injury management 
using an automated assessment of 
optimal cerebral perfusion pressure: the 
COGiTATE phase II study protocol
Erta Beqiri,   1,2 Peter Smielewski,1 Chiara Robba,3 Marek Czosnyka,1 
Manuel Teixeira Cabeleira,1 Jeanette Tas,4 Joseph Donnelly,1 Joanne G Outtrim,5 
Peter Hutchinson,1 David Menon,5 Geert Meyfroidt,6 Bart Depreitere,6 
Marcel J Aries,4 Ari Ercole5
To cite: Beqiri E, Smielewski P, 
Robba C, et al.  Feasibility of 
individualised severe traumatic 
brain injury management using 
an automated assessment 
of optimal cerebral perfusion 
pressure: the COGiTATE phase 
II study protocol. BMJ Open 
2019;9:e030727. doi:10.1136/
bmjopen-2019-030727
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
030727).
Received 30 March 2019
Revised 23 July 2019
Accepted 21 August 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Erta Beqiri;  
 erta. beqiri@ gmail. com
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
Strengths and limitations of this study
 ► First randomised controlled trial prospectively eval-
uating the feasibility and effectiveness of targeting 
a cerebral autoregulation-guided cerebral perfusion 
pressure (CPP) management in severe traumatic 
brain injury patients.
 ► For a maximum of 5 days, every 4 hours the at-
tending clinicians are asked to review the next CPP 
target, through a provided custom made bedside 
software. Clinicians are allowed to overrule the sug-
gested targets in both study arms.
 ► The adjusted CPPopt calculation algorithm and the 
study custom made software module are presented.
 ► The study was powered to accomplish a relative in-
crease of 20% of monitored time with CPP close to 
individual CPPopt target.
 ► The study is not designed to assess differences in 
clinical outcome.
AbStrACt
Introduction Individualising therapy is an important 
challenge for intensive care of patients with severe 
traumatic brain injury (TBI). Targeting a cerebral perfusion 
pressure (CPP) tailored to optimise cerebrovascular 
autoregulation has been suggested as an attractive strategy 
on the basis of a large body of retrospective observational 
data. The objective of this study is to prospectively assess 
the feasibility and safety of such a strategy compared with 
fixed thresholds which is the current standard of care from 
international consensus guidelines.
Methods and analysis CPPOpt Guided Therapy: 
Assessment of Target Effectiveness (COGiTATE) is a 
prospective, multicentre, non-blinded randomised, 
controlled trial coordinated from Maastricht University 
Medical Center, Maastricht (The Netherlands). The other 
original participating centres are Cambridge University NHS 
Foundation Trust, Cambridge (UK), and University Hospitals 
Leuven, Leuven (Belgium). Adult severe TBI patients 
requiring intracranial pressure monitoring are randomised 
within the first 24 hours of admission in neurocritical 
care unit. For the control arm, the CPP target is the Brain 
Trauma Foundation guidelines target (60–70 mm Hg); for 
the intervention group an automated CPP target is provided 
as the CPP at which the patient’s cerebrovascular reactivity 
is best preserved (CPPopt). For a maximum of 5 days, 
attending clinicians review the CPP target 4-hourly. The 
main hypothesis of COGiTATE are: (1) in the intervention 
group the percentage of the monitored time with measured 
CPP within a range of 5 mm Hg above or below CPPopt will 
reach 36%; (2) the difference in between groups in daily 
therapy intensity level score will be lower or equal to 3.
Ethics and dissemination Ethical approval has been 
obtained for each participating centre. The results will be 
presented at international scientific conferences and in 
peer-reviewed journals.
trial registration number NCT02982122
IntroduCtIon
The main aim of the intensive care manage-
ment of severe traumatic brain injury (TBI) 
patients is to prevent secondary injury. 
Central to this is the control of intracranial 
pressure (ICP) and maintaining an adequate 
cerebral perfusion pressure (CPP).1 Various 
international guidelines have recommended 
a variety of CPP targets over the years with the 
current iteration of Brain Trauma Founda-
tion (BTF) 2016 guidelines recommending a 
CPP tightly controlled between 60 and 70 mm 
Hg.2
However, it is unlikely that such a fixed 
therapeutic CPP target will be optimal for all 
individual TBI patients. Indeed, a failure to 
individualise therapies has been suggested as 
a reason for the difficulty to translate plau-
sible therapies into outcome benefit.1 With 
the demographics of TBI changing to an 
older patient group with more comorbidity, 
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the patient group is likely to become more heteroge-
neous.3 Furthermore, TBI pathobiology evolves4 and 
so, even within the same individual, optimal targets may 
vary over time. Potentially, individualising therapies and 
tailoring medical treatment to dynamic pathophysiology 
could offer a precision medicine approach with advan-
tages over the current ‘one size fits all’ strategy.
In health, cerebral autoregulation (CA) maintains 
a constant and adequate cerebral blood flow, thereby 
protecting the brain from both ischaemia and hyperper-
fusion in the face of inevitable changes in CPP. CA can 
frequently be impaired after TBI and this is related to 
poor outcome.5–7 Czosnyka et al5 first demonstrated that 
the moving correlation coefficient (pressure reactivity 
index, PRx) between slow changes in arterial blood pres-
sure (ABP) and ICP offers a surrogate method for the 
continuous bedside estimation of global CA.8
This concept has gained interest in the last decade 
with the observation that PRx and CPP often exhibit a 
U-shaped relationship over time with a minimum PRx 
occurring at a CPP for which cerebrovascular pressure 
reactivity is best preserved (or least impaired).9 Such 
observations suggest that targeting a CPP such that global 
CA is best maintained (‘optimal’ CPP—CPPopt) is a 
potentially attractive strategy for individualising care.
In recent years, there has been a great deal of work in 
trying to translate the concept CPPopt into an automated 
clinical application at the bedside.9–12 Such technolog-
ical improvements have been accompanied by a growing 
body of retrospective evidence (mostly single centre) of 
a robust association between poor outcome and devia-
tion from calculated CPPopt in severe TBI patients.9 10 
Prospective evaluation has, however, been lacking to date. 
Two prospective pilot studies evaluating autoregulation/
CPPopt tailored therapy in different settings demon-
strated an improvement in patient outcome.13 14 However, 
neither was a randomised study with a published inter-
vention protocol. Prospective evaluation is therefore 
urgently needed.
A phase II study is needed to resolve a number of 
outstanding issues before a properly powered and 
designed phase III trial can be conducted. In particular, it 
is not known whether it is feasible to track a dynamically 
changing physiological target in practice. Furthermore, 
retrospective studies have demonstrated that CPPopt 
tends to be higher than the 60–70 mm Hg fixed target 
from international guidelines.10 12 The physiological 
effects of this are difficult to assess from retrospective 
data. Targeting higher CPP values may require a higher 
therapeutic intensity (eg, greater use of vasopressors and 
fluids) and lead to extracranial complications (eg, pulmo-
nary, myocardial or renal injury). In addition, the very 
intervention of targeting CPPopt may itself affect the ICP 
behaviour, in terms both of mean values and presence of 
transient hypertensive episodes, and in general on brain 
compensatory reserve and compliance.
In summary, a prospective evaluation of the feasibility, 
safety and the physiological implications of CPPopt-guided 
management is now timely to inform the design of any 
future phase III study in severe TBI patients with ICP 
monitoring. In this paper we describe the protocol for 
such a phase II study: 'CPPOpt Guided Therapy: Assess-
ment of Target Effectiveness (COGiTATE)'.
MEthodS And AnAlySIS
design
COGiTATE is a prospective, multicentre, non-blinded, 
randomised, controlled trial in patients with severe TBI. 
Three tertiary centres are involved at the start of the 
study: Maastricht University Medical Center, Maastricht 
(The Netherlands), Cambridge University Hospitals 
NHS Foundation Trust, Cambridge (UK), and University 
Hospitals Leuven, Leuven (Belgium).
The patients are recruited in the first 24 hours of admis-
sion in the intensive care unit (ICU) and randomised 
into two treatment arms: the control group (CPP target 
given by the BTF guidelines—60–70 mm Hg) and the 
intervention group (CPP target given by the autoregula-
tion status—CPPopt). The duration of the study is 5 days. 
Other interventions (such as measures to control ICP) 
are unaltered from local protocols.
The first patient was enrolled on 16 February 2018.
objectives
The main objective of the study is to demonstrate that 
targeting CPP at CPPopt is feasible in TBI patients. The 
secondary objective is to demonstrate that targeting CPP 
at CPPopt is safe in TBI patients. The primary endpoints 
are (1) feasibility: the percentage of monitored time with 
measured CPP within a range of 5 mm Hg above or below 
CPPopt; (2) safety: daily therapy intensity level (TIL) 
score. The secondary endpoints are safety and physiology 
variables listed in box 1.
The main hypothesis of COGiTATE are: (1) in the inter-
vention group the percentage of the monitored time with 
measured CPP within a range of 5 mm Hg above or below 
CPPopt will reach 36%; (2) the difference in between 
groups in daily TIL score will be lower or equal to 3.
Methods and measurements
Data collection and online processing
In this study, ICP and ABP will be monitored as per normal 
clinical practice in the units: ICP will be recorded by a 
parenchymal ICP probe; ABP will be monitored by inva-
sive arterial cannulation in the radial artery and zeroed 
at the level of the foramen of Monroe. The data will be 
collected at a frequency >100 Hz (waveform resolution), 
and processed by means of ICM+ ® software (http:// 
icmplus. neurosurg. cam. ac. uk) at the bedside.
COGiTATE CPPopt algorithm
PRx is calculated as a moving correlation coefficient 
between 10 s averages of ICP and ABP waveforms in a 
window of 5 min. CPPopt is calculated using a multiwindow 
approach inspired by Depreitere et al,15 subsequently 
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box 1 Prespecified secondary outcomes
Safety variables
 ► ICP/CPP variability (representing adequacy/consistency of ICP 
control).
 ► Frequency and average duration of ICP spikes >20 mm Hg (associ-
ated with a dose-dependent harm).
 ► Frequency and average duration of CPP outside preset safety ranges 
(50–100 mm Hg).
 ► Mean daily RAP (correlation between ICP amplitude and ICP) index 
(as measure of brain compensatory reserve).
 ► Analysis of routine CT head scans for evidence of differences in con-
tusion, cerebral oedema and haemorrhage.
 ► Mean daily vasopressor dose; necessity and dose of inotropic 
support.
 ► Incidence of troponin rise and ECG changes stratified by day (as 
measure of cardiac complications).
 ► Incidence of serum creatinine rise (as measure of renal 
complications).
 ► Mean daily fluid balance.
 ► Mean daily oxygen arterial pressure/oxygen inspired fraction 
(PaO2/FiO2) ratio + oxygenation index (as measure of pulmonary 
complications).
 ► Intensive care survival, and Glasgow Coma Score at ICU discharge.
Physiology variables
 ► Mean daily MAP.
 ► Mean PRx.
 ► Mean daily PRx at CPPopt.
 ► Mean daily cerebral microdialysis lactate/pyruvate ratio.
 ► Brain tissue glucose as well as brain tissue oxygen tension (PbtO2 
and PbtO2/PaO2 ratio).
 ► Near infrared spectroscopy.
CPP, cerebral perfusion pressure; CPPopt, optimal cerebral perfusion pressure; 
ICP, intracranial pressure; MAP, mean arterial blood pressure; PRx, pressure 
reactivity index; RAP, compensatory reserve index.
implemented in ICM+ and investigated in a retrospective 
TBI data set by Liu et al.12 The algorithm has been further 
adapted to make it more suitable for prospective bed-side 
use.
At each time point, 36 PRx-CPP plots are generated 
from past data windows of increasing duration ranging 
from 2 to 8 hours, using incremental steps of 10 min. 
Prior to that, CPP time series are preprocessed with a 
5 min duration median filter and PRx data are Fisher 
transformed.16 Subsequently, all the data points are 
divided into groups corresponding to CPP bins of 5 mm 
Hg length, within 40–120 mm Hg range of CPP values. 
For each bin, mean PRx and CPP values are used to fit 
a second order polynomial describing the theoretical 
U-shape, with its nadir determining CPPopt. This process 
is repeated for each progressively longer data window. 
Individual results undergo certain quality control criteria 
and the accepted values are combined using weighted 
average operation, as detailed below. The calculations 
are repeated every minute and the resulting time series 
is finally subjected to an exponentially weighted average 
(EWA) filter of 2 hours of duration (details below), 
forming the CPPopt time trend and giving the current 
CPPopt target recommendation.
The curve fitting process for each time window follows 
the algorithm described by Aries et al10 with additional 
criteria as follows:
1. Each CPP bin must represent at least 3% of the total 
data count. In this way, CPP values that are very scarce-
ly represented, likely due to short spikes or drops, but 
not to the physiological trend, will be disregarded.
2. At least 50% of the data in the time window must be 
included in the curve fit.
3. A PRx variation of at least 0.2 is mandated (thus reject-
ing flatter PRx-CPP curves).
4. The PRx range of interest is enforced to be be-
tween −0.3 and 0.6: the algorithm will not return any 
CPPopt value when PRx is always very high (indicating 
a complete loss of pressure reactivity) or always very 
low (pressure reactivity preserved at each CPP value).
5. The coefficient of determination of the fitted curve 
R2full (calculated also for the bins excluded from the 
curve fitting process) must be at least 0.2.
The weights for combining the CPPopt calculations are 
given by the following formula:
 
weight=R2full ∗
{
1, shape = P
0, shape = NP 
where P and NP stand for parabolic (U-shape curve) 
and non-parabolic (non-U shape curve), respectively. In 
this way, in the COGiTATE study only parabolic curves 
are taken into account.
The EWA weight is calculated as (1-α)k where k is the 
distance, in number of samples, from the current sample 
and α is set at 0.1. In this way, more recent CPPopt values 
contribute more to the final calculation.
The curve fit and the weighting heuristics were chosen 
based on their performance in our retrospective data set, 
with regards to the resulting CPPopt time series lowest 
short term variability, ability to reject non-physiological 
values, and greatest discrimination from values generated 
from randomised, surrogate, signals (unpublished data).
The missing data limit of the calculation is set at 50%, 
therefore at least 4 hours of continuously acquired data 
are necessary to generate the first CPPopt value.
Assessment of compliance
Compliance with the protocol will be assessed at 4 hourly 
CPP treatment reviews and by investigators from the 
research team three times per day. The 4-hour interval is 
a pragmatic choice and reflects results from visualisation 
studies which suggested that CPPopt changes over a time 
frame of 4–8 hours, making the 4 hours an appropriate 
choice.17 To facilitate the compliance assessment, a custom 
module has been added to the ICM+ software that imple-
ments the alert and review system designed specifically 
for this trial. During the review time points, a CPP target 
is suggested by the software according to the protocol 
and depending on the arm. The treating clinicians may 
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deviate from protocol but must provide their proposed 
target and clinical rationale for deviation in a structured 
short questionnaire presented by the software (see online 
supplementary files 1 and 2).
outcome measures
Feasibility
Percentage of monitored time with measured CPP within 
a range of 5 mm Hg above or below CPPopt.
The primary objective of the study is to demonstrate 
that it is clinically feasible to individualise CPP at CPPopt 
in TBI patients continuously over time, and demon-
strate that we could achieve acceptable concordance 
with CPPopt. We also wish to explore whether a CPPopt-
guided strategy resulted in a significant difference in CPP 
compared with the controls. Specifically, we aim to assess 
whether the application of a CPPopt oriented protocol 
provides a greater percentage of time during which 
CPP is within 5 mm Hg above or below the calculated 
CPPopt during the first 5 days of admission. Analysis of 
retrospective dataset in patients not managed according 
to the CPPopt concept showed that on average 30% of 
the monitored time CPP fell within 5 mm Hg margin of 
CPPopt (unpublished data). This study was powered to 
target an increase of the monitored time by 20% (rela-
tive increase), meaning increase from 30% to 36% of the 
monitored time within the 5 mm Hg margin of CPPopt, 
in the intervention group.
Safety: daily TIL score
The main secondary objective of the study is to demon-
strate that targeting CPPopt is safe. Safety is defined in 
two domains. First, COGiTATE aims to assess whether a 
dynamic target is associated with excess haemodynamic 
support or organ failure. Second, the study will assess 
whether such a therapy leads to either worse or more diffi-
cult ICP control by driving cerebral oedema. This will be 
assessed by looking for an excess of (potentially burden-
some) treatments to control ICP in the treatment arm as 
assessed by the use of the daily TIL score.18 A change in 
TIL score of >3 is representative of a significant escalation 
of TBI treatment from basic ICP management involving 
rescue therapies which are known to carry a clinically 
significant risk of harm. An increase of TIL score >3 is 
therefore expected to represent a clinically significant 
potentially harmful effect of CPPopt-guided treatment 
and the assessment of this will be the main secondary 
endpoint.
Safety: safety and physiology variables
Finally, we want to evaluate differences in physiological 
parameters between interventional and control arms 
(box 1). In particular, it is aimed to assess whether CPPopt-
guided therapy itself affects autoregulation indexes 
compared with the control group. Brain oxygenation 
and tissue chemistry will be assessed in those patients for 
which additional monitoring was considered clinically 
justifiable.
Study population
The study population consists of unconscious adult 
patients with severe TBI admitted to the ICU of three 
academic hospitals in whom invasive ICP monitoring is 
clinically indicated.
Inclusion criteria: (1) any adult severe TBI patient (age 
>18 years) requiring multimodality monitoring and ICP-di-
rected therapy for at least 24 hours on the assessment of 
the recruiting team; (2) randomisation occurred within 
24 hours after ICU admission; (3) informed consent/
agreement obtained by a legally authorised representative 
before inclusion, accordingly to the local legislations.
Exclusion criteria: (1) patients <18 years old; (2) known 
pregnancy; (3) moribund at presentation (eg, bilaterally 
absent pupillary responses); (4) patients with primary 
decompressive craniectomy (DC); (5) patients already 
enrolled in one other intervention study.
If patients are treated with a secondary DC, they will end 
the study as it is unknown how brain physiology changes 
after a DC and the calculation of CPPopt is poorly vali-
dated in such patients. Data up to the time of the DC will 
be retained for analysis. Once the study is terminated, 
the patients’ CPP will be managed according to the BTF 
guidelines.
Study arms and randomisation
Patients are randomised to either standard CPP protocol 
therapy (control group) or to CPPopt-guided manage-
ment of CPP (intervention group). Block randomisation 
by centre are used to ensure a uniform distribution of 
patients. Randomisation is done electronically on recruit-
ment using a purpose built electronic Case Report Form 
(eCRF) hosted by the Clinical Trial Center Maastricht in 
Maastricht with a secure web interface.
Patient allocated to the control group are managed 
according to the most recent BTF guidelines2 which 
recommend maintaining CPP between 60 and 70 mm 
Hg. In this group, online autoregulation information is 
hidden from the treating team although available to the 
study team for analysis.
Patients allocated to the intervention group are 
managed according so as to target CPPopt, when there is 
sufficient data for it to be available. If at the fixed review 
time points the CPPopt value is not available (eg, due to 
noisy or missing data) or it is outside of the safety limits 
(50–100 mm Hg), the protocol advises to follow a CPP 
target at the discretion of the clinician: this may be either 
the BTF guideline target or a previous target. As a safety 
precaution, the maximum difference in CPP target value 
suggested by the software at the new review time from the 
current target value has been limited to ±10 mm Hg to 
avoid potentially harmful jumps in CPP.
A flowchart of the patients’ inclusion, randomisation 
and study procedures in the COGiTATE trial is presented 
in figure 1.
Sample size
The sample size justification is based on the primary 
endpoint for the feasibility objective. The analyses will be 
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Figure 1 Flowchart of the patients’ inclusion, randomisation 
and study procedures in the COGiTATE trial. BTF, Brain 
Trauma Foundation; CPP, cerebral perfusionpressure; 
CPPopt, optimal cerebral perfusion pressure; ICP, intracranial 
pressure; ICU, intensive care unit; TBI, traumatic brain injury.
conducted according to the intention-to-treat principle, 
therefore all the enrolled and randomised patients will be 
included in the analysis, regardless of their compliance 
with the protocol. Sample sizes were determined using 
the R statistical language19 and the PWR package.20 A 
significance of 5% and power of 80% were assumed.
As described in the outcome measures paragraph, the 
primary endpoint for the main objective, feasibility, is the 
percentage of monitored time with measured CPP within 
a range of 5 mm Hg above or below CPPopt. Retrospec-
tive analysis in unpublished data showed that on average 
patients spent a mean (+SD) of 30% (+8%) of their 
monitored time with measured CPP within 5 mm Hg of 
CPPopt. In the absence of prospective data, we powered 
COGiTATE study to target a relative increase in CPPopt 
target adherence by 20% (a pragmatic choice but justi-
fiable on typical differences seen between good/poor 
outcome in the retrospective data), that is, from 30% to 
36% of monitored time within the CPPopt target margin, 
while keeping the SD at 8%. This produced a desired 
sample size of 56, which was increased to 60 patients, 
to allow for dropout, technical problems or need for a 
non-parametric analysis.
The primary endpoint for the safety secondary objec-
tive is to assess whether there is an increase of the daily 
TIL score of >3 in the CPPopt treatment arm. We regard 
an increase of daily TIL of 3 as a significant effect as it 
represents a difference comparable to one treatment tier 
and in comparison with typical TIL variability from pilot 
data. Conversely, a TIL score increase of 2 can be expected 
in the intervention group because two points are counted 
for CPP-related therapy (vasopressor therapy/fluids), so 
this could be not interpreted as a significant worsening 
of TBI therapy. We estimate, for 80% power and 5% 
significance an averaged change in daily TIL score of 3 
would require an n=25 in each arm (although this is a 
secondary endpoint and this estimation does not correct 
for multiple comparisons).
data storage
High frequency ICP and ABP signals are recorded contin-
uously and processed to obtain CPP and CPPopt. The 
values are subsequently transferred to secure local servers 
for offline analysis. Only the local study teams have access 
to the server.
Additional clinical and biochemical data (severity of 
injury and hospital course) use the patient’s medical 
record as source data and are subsequently transcribed 
to the eCRFs with access limited to members of the study 
team only.
Imaging data and radiological reports obtained from 
the CT scans, are collected and stored on a secure local 
server.
The patients enrolled in the study and randomised, 
are assigned a study deidentification number that will be 
used in the data collection forms. An enrolment log is 
used in each centre to keep the link between the partici-
pants’ identity and the study number. This log is secured 
in password-protected local servers to which only the 
local study coordinator and the members of the research 
team have access. The data transmitted to the data coor-
dinating centre in Maastricht will be entirely deidentified.
Paper copies of the data, consent forms and protocols 
will be stored locally. Personal data will be destroyed after 
1 year. Fifteen years after the completion of the study, all 
the paper study files and all the stored electronic files will 
be destroyed.
Statistical analysis
The data will be analysed on an intention-to-treat basis 
with all randomised patients included in the analysis. For 
the primary endpoint, the total time (in minutes) each 
patient had CPP values close (±5 mm Hg) to CPPopt will 
be calculated and analysed in a blinded manner by the 
study team. The fraction of time that CPP will be within 
5 mm Hg of CPPopt, will represent the primary analysis 
for this outcome. For secondary analysis, different devia-
tion thresholds (7.5 and 10 mm Hg) will also be assessed. 
The two groups will be compared with an unpaired t-test 
(or a non-parametric equivalent in the event of a signif-
icant departure the normal distribution). Multivariable 
linear models will be used to control for the covariates 
centre, age, Glasgow Coma Score after resuscitation, 
pupil reactivity, presence of extracranial injury and 
primary craniotomy.
For the secondary safety endpoint, a t-test (or non-para-
metric equivalent) will be used for the statistical compar-
ison of the TIL score, vasopressor and fluid use and organ 
dysfunction summary measures between the two groups. 
If necessary, multivariable linear regression analysis will 
be used to adjust for imbalances in main prognostic vari-
ables between the two groups.
For the other secondary safety and physiology endpoints, 
the results will be presented as mean (SD) for continuous 
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variables and as frequencies (%) for categorical variables. 
Intervention and control group will be compared using 
a t-test or non-parametric equivalent for continuous vari-
ables and χ2/Fisher test for categorical variables.
Patient and public involvement
Improving outcomes from TBI is a known area of societal 
importance.3 Patients and public were not involved in the 
study design and, as patients in this study were uncon-
scious, they could not be otherwise involved. The results 
will be disseminated through peer-reviewed publications 
and presentation at international conferences as well as 
by social media and the study website ( www. cppopt. org) 
which also contains information for the public.
EthICS And dISSEMInAtIon
Ethical considerations
The trial is conducted according to the Declaration of 
Helsinki and the respective participating countries laws 
governing clinical research, and the principles of Good 
Clinical Practice.
Enrolled subjects, by definition, lack capacity to consent 
due to their level of consciousness at presentation. The 
informed consent procedure involves identifying a legally 
authorised representative of the patient, whose opinion 
is sought about the participant’s wishes and feelings in 
relation to the project, and whether he/she would want 
to take part to the study. When available, a legally autho-
rised representative (accordingly to the local laws) is then 
approached by a member of the clinical team, to inform 
them of the research study. If he/she agrees, a member 
of the research team will then provide further verbal and 
written explanation of the research study. If the family 
member/legal representative advises that the patient 
would want to take part in the study, the patient will be 
enrolled.
For this study, it was deemed physiologically important 
to begin CPPopt therapy as early as possible following the 
injury since pathobiological determinants of inflamma-
tion and oedema are likely to be determined in the first 
24–48 hours after injury. Therefore, if a legally authorised 
representative is not identified within the first 12 hours 
after ICU admission, depending on the local country laws, 
the patient may be included via agreement with one of 
the treating clinicians not involved in the study (in UK), 
or using a deferred consent procedure (in Netherlands 
and Belgium). Following enrolment via deferred consent, 
if a legal representative does not agree for the patient to 
continue their participation in the study within 24 hours 
the patient will be withdrawn.
If the patient regains consciousness and capacity during 
their admission (ICU or hospital admission according to 
the local protocols), the patient will be approached to 
provide consent for their participation in the study. If the 
patient declines, they will be given the option to have data 
collected retained for analysis or destroyed completely.
Safety considerations
Safety of this study is independently monitored by an 
external clinical trials agency (Clinical Trial Center Maas-
tricht, Oxfordlaan 70, 6229 EV Maastricht (NL)) who 
will also have oversight of data quality. For this cohort of 
patients, a mortality rate of 25% and a severe disability 
rate of 30% is expected at baseline. However, it is 
unknown whether targeting CPPopt, which may typically 
be higher than a fixed range of 60–70 mm Hg could drive 
further oedema or contusion expansion over the next 
days or lead to respiratory, renal or myocardial injury 
due to greater vasopressor requirements. Therefore, the 
followings are reported: increases in oedema or haemor-
rhages on repeated brain CT, troponin rise and/or ECG 
changes, NT-proBNP rise, significant serum creatinine 
rise and PaO2/FiO2 ratio <300. Severe adverse events and 
predefined adverse events that are commonly expected 
in TBI patients will also be recorded and reported. 
Glasgow Outcome Scale Extended at 6 months will also 
be collected as part of institutional practice or other 
observational studies.
dissemination
The results of this study will be presented at international 
scientific conferences and in peer-reviewed journals, 
regardless of the trial outcome.
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